Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial?

Hiddo J. Lambers Heerspink; Dick de Zeeuw

doi:10.1159/000292501

Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial?

Hiddo J. Lambers Heerspink, Dick de Zeeuw^*

^*Corresponding author for this work

Groningen Kidney Center (GKC)

Research output: Contribution to journal › Editorial › Academic › peer-review

39 Citations (Scopus)

Original language	English
Pages (from-to)	466-467
Number of pages	4
Journal	American Journal of Nephrology
Volume	31
Issue number	5
DOIs	https://doi.org/10.1159/000292501
Publication status	Published - 2010

Keywords

CARDIOVASCULAR EVENTS
DIABETIC NEPHROPATHY
KIDNEY-FUNCTION
HYPERTENSION
INSUFFICIENCY
ALBUMINURIA
RISK

Access to Document

10.1159/000292501

Handle.net

Persistent link

Cite this

@article{d0c5a8d9fe0d4586966118dc566286a9,

title = "Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial?",

keywords = "CARDIOVASCULAR EVENTS, DIABETIC NEPHROPATHY, KIDNEY-FUNCTION, HYPERTENSION, INSUFFICIENCY, ALBUMINURIA, RISK",

author = "{Lambers Heerspink}, {Hiddo J.} and {de Zeeuw}, Dick",

year = "2010",

doi = "10.1159/000292501",

language = "English",

volume = "31",

pages = "466--467",

journal = "American Journal of Nephrology",

issn = "0250-8095",